Positive Chrohn's Disease Results May Have Implications for Potential Lupus Drug

Monday, October 22, 2012

A clinical trial in the autoimmune disease Chrohn's Disease showed positive results for an experimental drug laquinimod that is also in development for lupus. Laquinimod is a novel oral immunomodulator in clinical development by Teva Pharmaceutical Industries and Active Biotech, for the treatment of multiple sclerosis (MS), Crohn's disease (CD) and systemic lupus erythematosus (SLE or lupus). The findings presented at a European medical meeting showed nearly 50% remission of Chrohn's Disease as compared to placebo.

Read More from Teva Pharmaceuticals and Active Biotech.